Impact of sphingomyelin levels on coronary heart disease and left ventricular systolic function in humans

Nutrition and Metabolism

Volumn 8, Issue , 2011, Pages

  Chen, Xueying ^a   Sun, Aijun ^a   Zou, Yunzeng ^a   Ge, Junbo ^a   Lazar, Jason M ^b   Jiang, Xian Cheng ^c  

^a FUDAN UNIVERSITY   (China)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c SUNY Downstate Medical Center   (United States)

Author keywords

coronary heart disease; left ventricular ejection fraction; lipids; sphingomyelin

Indexed keywords

APOLIPOPROTEIN B; SPHINGOMYELIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBROGENESIS; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE;

EID: 79955107751     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-8-25     Document Type: Article

References (33)

1. Absorption and lipoprotein transport of sphingomyelin. A Nilsson RD Duan, J Lipid Res 2006 47 154 171 16251722 (Pubitemid 43107459)
2. Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. PV Subbaiah MH Davidson MC Ritter W Buchanan JD Bagdade, Atherosclerosis 1989 79 157 166 10.1016/0021-9150(89)90120-2 2597225 (Pubitemid 19226324)
3. Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 1. Chemical composition of very low density lipoproteins in rabbits. JL Rodriguez GC Ghiselli D Torreggiani CR Sirtori, Atherosclerosis 1976 23 73 83 10.1016/0021-9150(76)90119-2 233765
4. The synthesis of phospholipids in human atheromatous lesions. DB Zilversmit CE Mc PH Jordan WS Henly RF Ackerman, Circulation 1961 23 370 375 13788499
5. The response-to-retention hypothesis of early atherogenesis. KJ Williams I Tabas, Arterioscler Thromb Vasc Biol 1995 15 551 561 7749869
6. The response-to-retention hypothesis of atherogenesis reinforced. KJ Williams I Tabas, Curr Opin Lipidol 1998 9 471 474 9812202 (Pubitemid 28495557)
7. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. SL Schissel J Tweedie-Hardman JH Rapp G Graham KJ Williams I Tabas, J Clin Invest 1996 98 1455 1464 10.1172/JCI118934 8823312 (Pubitemid 26322072)
8. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. CM Devlin AR Leventhal G Kuriakose EH Schuchman KJ Williams I Tabas, Arterioscler Thromb Vasc Biol 2008 28 1723 1730 10.1161/ATVBAHA.108.173344 18669882
9. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. T Jeong SL Schissel I Tabas HJ Pownall AR Tall X Jiang, J Clin Invest 1998 101 905 912 10.1172/JCI870 9466986 (Pubitemid 28096088)
10. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. AS Plump JD Smith T Hayek K Aalto-Setala A Walsh JG Verstuyft EM Rubin JL Breslow, Cell 1992 71 343 353 10.1016/0092-8674(92)90362-G 1423598
11. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. MR Hojjati Z Li H Zhou S Tang C Huan E Ooi S Lu XC Jiang, J Biol Chem 2005 280 10284 10289 10.1074/jbc.M412348200 15590644 (Pubitemid 40395884)
12. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. TS Park RL Panek SB Mueller JC Hanselman WS Rosebury AW Robertson EK Kindt R Homan SK Karathanasis MD Rekhter, Circulation 2004 110 3465 3471 10.1161/01.CIR.0000148370.60535.22 15545514 (Pubitemid 39602225)
13. Plasma sphingomyelin level as a risk factor for coronary artery disease. XC Jiang F Paultre TA Pearson RG Reed CK Francis M Lin L Berglund AR Tall, Arterioscler Thromb Vasc Biol 2000 20 2614 2618 11116061
14. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. A Schlitt S Blankenberg D Yan H von Gizycki M Buerke K Werdan C Bickel KJ Lackner J Meyer HJ Rupprecht XC Jiang, Nutr Metab (Lond) 2006 3 5 10.1186/1743-7075-3-5
15. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. JC Nelson XC Jiang I Tabas A Tall S Shea, Am J Epidemiol 2006 163 903 912 10.1093/aje/kwj140 16611667
16. Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis. J Yeboah C McNamara XC Jiang I Tabas DM Herrington GL Burke S Shea, Arterioscler Thromb Vasc Biol 2010 30 628 633 10.1161/ATVBAHA.109.199281 20032291
17. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. MR Hojjati XC Jiang, J Lipid Res 2006 47 673 676 16371647 (Pubitemid 43345608)
18. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. TK Hailemariam C Huan J Liu Z Li C Roman M Kalbfeisch HH Bui DA Peake MS Kuo G Cao R Wadgaonkar XC Jiang, Arterioscler Thromb Vasc Biol 2008 28 1519 1526 10.1161/ATVBAHA.108.168682 18566297
19. [Changes of nitric oxide and endothelin serum level after carotid balloon denudation or stent assisted angioplasty: an experimental and clinical observation]. JC Liu DM Wang JN Qian YG Li LJ Wang XL Jiang LL Zhai J Lu P Qi, Zhonghua Wai Ke Za Zhi 2009 47 423 426 19595226
20. The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen. G Lozanski F Berthier I Kushner, Biochem J 1997 328 Pt 1 271 275 9359864 (Pubitemid 27499470)
21. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. MM Redfield SJ Jacobsen JC Burnett Jr DW Mahoney KR Bailey RJ Rodeheffer, JAMA 2003 289 194 202 10.1001/jama.289.2.194 12517230 (Pubitemid 36068707)
22. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. B Liu N Andrieu-Abadie T Levade P Zhang LM Obeid YA Hannun, J Biol Chem 1998 273 11313 11320 10.1074/jbc.273.18.11313 9556624 (Pubitemid 28204985)
23. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. H Oral GW Dorn DL Mann, J Biol Chem 1997 272 4836 4842 10.1074/jbc.272.8.4836 9030540 (Pubitemid 27090030)
24. Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes. A Amadou A Nawrocki M Best-Belpomme C Pavoine F Pecker, Am J Physiol Cell Physiol 2002 282 1339 1347 11997249
25. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. M Cailleret A Amadou N Andrieu-Abadie A Nawrocki C Adamy B Ait-Mamar F Rocaries M Best-Belpomme T Levade C Pavoine F Pecker, Circulation 2004 109 406 411 10.1161/01.CIR.0000109499.00587.FF 14732751 (Pubitemid 38133911)
26. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. C Pavoine F Pecker, Cardiovasc Res 2009 82 175 183 19176603
27. Phospholipid composition in the rat heart exposed to pressure overload from birth. L Mrnka O Novakova V Pelouch F Novak, Physiol Res 1996 45 83 85 8884928 (Pubitemid 26091969)
28. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. J Liu C Huan M Chakraborty H Zhang D Lu MS Kuo G Cao XC Jiang, Circ Res 2009 105 295 303 10.1161/CIRCRESAHA.109.194613 19590047
29. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis. Y Fan F Shi J Liu J Dong HH Bui DA Peake MS Kuo G Cao XC Jiang, Arterioscler Thromb Vasc Biol 2010 30 2114 2120 10.1161/ATVBAHA.110.213363 20814016
30. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. K Skalen M Gustafsson EK Rydberg LM Hulten O Wiklund TL Innerarity J Boren, Nature 2002 417 750 754 10.1038/nature00804 12066187 (Pubitemid 34640629)
31. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. SL Schissel GA Keesler EH Schuchman KJ Williams I Tabas, J Biol Chem 1998 273 18250 18259 10.1074/jbc.273.29.18250 9660788 (Pubitemid 28334747)
32. Serum sphingomyelin levels are related to the clearance of postprandial remnantlike particles. A Schlitt MR Hojjati H von Gizycki KJ Lackner S Blankenberg B Schwaab J Meyer HJ Rupprecht XC Jiang, J Lipid Res 2005 46 196 200 15547302 (Pubitemid 40271082)
33. Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis. Y Fan F Shi J Liu J Dong HH Bui DA Peake MS Kuo G Cao XC Jiang, Arterioscler Thromb Vasc Biol 2010